The new brand and identity encapsulates the commitment of expansion and growth following the merger of Histo-Scientific Research Laboratories with Vet Path Services and investment from Ampersand Capital Partners
Mount Jackson, VA and Mason, OH – March 11, 2018 – Histo-Scientific Research Laboratories, Inc. (HSRL), a leading provider of research and preclinical histology, pathology, and archiving services, today announced the business’ rebranding following the merger with Vet Path Services (VPS) and the accompanying growth investment from Ampersand Capital Partners. The company will now be known as StageBio.
“Over the past 20 years, HSRL has built a strong reputation for quality and reliability and we are excited to maintain our position in the market as a trusted provider of critical services in the pre-clinical research and development market under a new name,” said Mr. Thomas Galati, StageBio CEO. The rebrand is designed to signify the company’s commitment to expand its service offering for the biopharma, medical device, and contract research industries and unify both HSRL and VPS under one name.
The merger of HSRL and VPS is an example of what is to come for StageBio. The company is now positioned to provide its customers with fully integrated histopathology services including tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to FDA approval, detailed pathology reporting for GLP studies, medical device pathology, and immunohistochemistry.
The new brand and company will be formally launched at the Society of Toxicology meeting in Baltimore, March 10-14. StageBio invites you to join them at Booth #3637 to learn more about the new company and how they can meet your histopathology needs.
Please visit www.stagebio.com to explore the new website and learn more about the new services being offered.
StageBio is the leading provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. We provide our customers with a fully integrated breadth of histopathology services, including tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to FDA approval, detailed pathology reporting for GLP studies, medical device pathology and immunohistochemistry. We operate three state-of-the-art sites in the US, with substantial continued investment in our facility and technology infrastructures to meet the growing demand for high-quality histopathology services. With 18 board-certified veterinary pathologists and over 50 laboratory technicians on staff, we are ideally positioned to deliver on our unified commitment to quality, scientific integrity and customer service excellence.
For further information contact:
Director of Corporate Development